TXGNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
10x Genomics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$69.89+0.03 (+0.04%)
Close on Oct 19, 2026
- Market cap
- $9.08B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$58.06 (+490.8%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
10x Genomics, Inc. saw revenue fall 4.3% to $616.91M over the twelve months to Jun 30, 2026. Free cash flow was $121.44M, up 113.5% from a year earlier.
Revenue
$616.91M
-4.3% vs. a year earlier
Operating income
-$88.38M
TTM Q2 2026
Free cash flow
$121.44M
+113.5% vs. a year earlier
EPS, diluted
-$0.59
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $9.08B
- P/E ratio
- –
- Price to sales
- 14.73
- Price to book
- 11.00
- Dividend yield
- –
- Free cash flow yield
- 1.34%
Fundamentals
- Revenue
- $616.91M
- Net income
- -$75.13M
- EPS, diluted
- -$0.59
- Free cash flow
- $121.44M
- Book value per share
- $6.35
- Diluted shares
- 130M
Ten years at a glance
Fiscal years 2016 to 2025 and trailing twelve months, USD
Revenue
$616.91M-4.3% YoY
Gross profit
$432.03M-3.5% YoY
Operating income
-$88.38M
Net income
-$75.13M
EPS, diluted
-$0.59
Free cash flow
$121.44M+113.5% YoY
Reported periodTrailing twelve months